The choice of breast cancer as an experimental model for these studies was based on the numerous clinical trials evaluating metronomic chemotherapy in breast cancer patients as an adjuvant or metastatic therapy used alone or in combination with other drugs such as methotrexate, capecitabine, or vinorelbine as well as targeted agents such as bevacizumab and trastuzumab, or an aromatase inhibitor23–28. The gene discussed is CYP19A1; the disease is breast cancer.